The research carried out at Reading University, and part funded by GW, has demonstrated for the first time that a previously unstudied chemical present in cannabis, called cannabidivarin (or CBDV) could lead to more effective treatment for people with epilepsy.
In the study the chemical strongly suppressed seizures, GW said.
GW already has already developed and commercialised a cannabis based treatment – in the form of a spray – for people suffering from multiple sclerosis. And it continues to explore other potential treatments.
"These results further underscore the potential of naturally-derived cannabinoids as medicines to treat a broad range of diseases,” said Dr Stephen Wright, GW Pharmaceuticals’ director of research and development.
“GW has established a track record of discovering and commercialising such compounds with Sativex®now on the market for treating spasticity associated with multiple sclerosis and in late stage development for the treatment of cancer pain.
“Our research into CBDV has consistently produced highly promising results demonstrating its potential as a novel anticonvulsant and GW hopes during 2013 to advance CBDV into human clinical trials."